查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1572977

生技药品外包市场：按产品类型、应用、供应商、服务类型、最终用户、治疗领域 - 2025-2030 年全球预测

Biologics Outsourcing Market by Product Type, Application, Source, Service Type, End User, Therapeutic Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生技药品外包市场价值为205.6亿美元，预计到2024年将达到228.7亿美元，复合年增长率为12.18%，到2030年将达到459.8亿美元。

生技药品外包涉及将生物製药的製造和开发过程委託给专业的第三方服务供应商。其范围包括细胞株开发、製程开发、分析表征、配方和生产等活动。这种需求源自于生物製药，包括蛋白质、抗体和基因疗法药物，需要专门的专业知识和设备。应用范围包括希望加快产品开发、减少内部设备资本支出以及将资源集中在核心竞争力的製药和生物技术公司。最终用途范围延伸至肿瘤学、自体免疫疾病和罕见遗传疾病等治疗领域。影响生技药品外包市场的主要成长要素包括慢性病的增加、生物技术的进步以及生物製药开发投资的增加。由于较低的营运成本和扩大的医疗基础设施，新兴市场提供了潜在的商机。抓住此类机会的建议包括与当地服务供应商建立策略联盟以及参与技术转移。然而，挑战依然存在，包括严格的监管要求、对智慧财产权安全的担忧以及不同的品质标准。这些因素可能会阻碍市场扩张，特别是在法律规范较不成熟的地区。儘管存在这些挑战，一次性技术、自动化和高级分析等领域的创新在提高生技药品生产的效率和扩充性方面具有巨大潜力。公司可以专注于开发具有成本效益的生物加工技术和个人化医疗，以保持竞争优势。此外，数位转型，包括人工智慧和机器学习在生技药品研发和製造中的整合，可能会带来重大突破。该市场的特点是充满活力且竞争激烈，大型合约开发和受託製造厂商（CDMO）收购利基服务供应商以扩大其能力和地理范围并加强其市场地位，这往往会导致更大的整合。

主要市场统计
基准年[2023] 205.6亿美元
预测年份 [2024] 228.7亿美元
预测年份 [2030] 459.8亿美元
复合年增长率（%） 12.18%

市场动态：快速发展的生技药品外包市场的关键市场洞察

供需的动态交互作用正在改变生技药品外包市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 严格的监管要求以及生技药品製造中合规专业知识的需求
    • 推动生技药品製造外包的成本效益和缩短时间的优势
    • 製药公司扩大生技药品管道需要外部製造支持
    • 外包公司采用一次性技术和连续生物加工
  • 市场限制因素
    • 缺乏专业生技药品製造和工艺开发的熟练劳动力
    • 委託过程中生物製药品质的变化导致潜在的风险和责任
  • 市场机会
    • 有机会与寻求经济实惠的生技药品製造解决方案的中小型生物技术公司合作
    • 利基治疗领域对专业生技药品开发服务的需求不断增长
    • 加强製药公司与合约研发组织在生技药品开发上的合作
  • 市场挑战
    • 管理生技药品外包市场中的供应链中断与物流挑战
    • 确保生技药品外包服务的成本效率，同时维持高品质标准

波特五力：驾驭生技药品外包市场的策略工具

波特的五力架构是了解生技药品外包市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解生技药品外包市场的外部影响

外部宏观环境因素在塑造生技药品外包市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解生技药品外包市场的竞争格局

对生技药品外包市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵生技药品外包市场供应商的绩效评估

FPNV 定位矩阵是评估生技药品外包市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製生技药品外包市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对生技药品外包市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 严格的监管要求以及生技药品製造中合规专业知识的需求
      • 成本效率和缩短时间的优势推动了生物製药製造的外包
      • 製药公司扩大生物製药管道需要外部製造支持
      • 外包公司采用一次性技术和连续生物加工
    • 抑制因素
      • 专业生技药品製造和工艺开发的熟练劳动力有限
      • 外包过程中生物製品品质的变化导致潜在的风险和责任
    • 机会
      • 有机会与寻求负担得起的生技药品製造解决方案的小型生物技术公司合作
      • 利基治疗领域对专业生技药品开发服务的需求不断增长
      • 扩大製药公司与合约研究组织在生物製药开发的合作
    • 任务
      • 生技药品外包市场因应供应链中断与物流挑战
      • 确保生技药品外包服务的成本效率，同时维持高品质标准
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生技药品外包市场：依产品类型

  • 反义、RNAi、分子治疗
  • 单株抗体
  • 其他生物製药
  • 重组蛋白
  • 疫苗

第七章生技药品外包市场：依应用分类

  • 心血管疾病
  • 免疫学
    • 过敏性疾病
    • 自体免疫疾病
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染
  • 神经病学
  • 肿瘤学
    • 癌症生物标记研究
    • 个人化癌症治疗
  • 其他应用

第八章生技药品外包市场：依来源分类

  • 哺乳动物的
  • 非哺乳动物
    • 细菌
    • 昆虫细胞
    • 植物细胞
    • 酵母菌

第九章生技药品外包市场：依服务类型

  • 分析和品管
  • 临床试验
  • 填充和整理操作
  • 製程开发
  • 监管服务

第 10 章生技药品外包市场：依最终用户分类

  • 生技公司
  • 合约研究组织（CRO）
  • 製药公司
  • 调查机构

第十一章依治疗领域分類的生技药品外包市场

  • 癌症
  • 心血管疾病
  • 感染疾病
  • 发炎和免疫疾病
  • 代谢紊乱
  • 神经系统疾病

第十二章美洲生技药品外包市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太生技药品外包市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲生技药品外包市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0467

The Biologics Outsourcing Market was valued at USD 20.56 billion in 2023, expected to reach USD 22.87 billion in 2024, and is projected to grow at a CAGR of 12.18%, to USD 45.98 billion by 2030.

Biologics outsourcing involves externalizing the production and development processes of biologic drugs to specialized third-party service providers. The scope includes activities such as cell line development, process development, analytical characterization, formulation, and production. This necessity arises from the complex nature of biologic drugs, which include proteins, antibodies, and gene therapies, demanding specialized expertise and facilities. Applications span across pharmaceuticals and biotechnology companies aiming to expedite product development, reduce capital expenditure on in-house facilities, and focus resources on core competencies. The end-use scope extends to therapeutic areas including oncology, autoimmune diseases, and rare genetic disorders. Key growth factors influencing the biologics outsourcing market include the increasing prevalence of chronic diseases, advancements in biotechnology, and growing investment in biologic drug development. Emerging markets offer potential opportunities, driven by lower operational costs and expanding healthcare infrastructures. Recommendations for capturing these opportunities include forming strategic alliances with local service providers and engaging in technology transfers. However, challenges persist, such as stringent regulatory requirements, concerns over intellectual property security, and variability in quality standards. These factors can hinder market expansion, particularly across regions with less mature regulatory frameworks. Despite these challenges, innovation in areas such as single-use technologies, automation, and advanced analytics holds significant promise for enhancing efficiency and scalability in biologics production. Companies could focus on the development of cost-effective bioprocessing technologies and personalized medicine to maintain competitive advantage. Furthermore, digital transformation, including the integration of artificial intelligence and machine learning in biologic R&D and manufacturing, can lead to significant breakthroughs. The market is characterized by a dynamic and competitive landscape, with a trend towards consolidation, as larger contract development and manufacturing organizations (CDMOs) acquire niche service providers to expand capabilities and geographical reach, thereby strengthening their market position.

KEY MARKET STATISTICS
Base Year [2023] USD 20.56 billion
Estimated Year [2024] USD 22.87 billion
Forecast Year [2030] USD 45.98 billion
CAGR (%) 12.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Outsourcing Market

The Biologics Outsourcing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Stringent regulatory requirements and the need for compliance expertise in biologics production
    • Cost-efficiency and time reduction benefits driving outsourcing of biologics manufacturing
    • Expansion of biologics pipelines by pharmaceutical companies necessitating external manufacturing support
    • Adoption of single-use technologies and continuous bioprocessing by outsourcing firms
  • Market Restraints
    • Limited availability of skilled workforce for specialized biologics manufacturing and process development
    • Variability in biological product quality during outsourcing leading to potential risks and liabilities
  • Market Opportunities
    • Partnership opportunities with smaller biotechnology firms seeking affordable biologics manufacturing solutions
    • Growing need for specialized biologics development services in niche therapeutic areas
    • Rising collaboration between pharmaceutical companies and contract research organizations for biologics development
  • Market Challenges
    • Managing supply chain disruptions and logistics challenges in the biologics outsourcing market
    • Ensuring cost efficiency while maintaining high quality standards in biologics outsourcing services

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Outsourcing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Outsourcing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Outsourcing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Outsourcing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Outsourcing Market

A detailed market share analysis in the Biologics Outsourcing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Outsourcing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Outsourcing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Outsourcing Market

A strategic analysis of the Biologics Outsourcing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Outsourcing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Biocon Limited, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Covance Inc., Eli Lilly and Company, Fujifilm Diosynth Biotechnologies, Genentech, Inc., Icon plc, Lonza Group AG, Merck KGaA, Novartis AG, Parexel International Corporation, Pfizer Inc., Samsung Biologics Co., Ltd., Sandoz International GmbH, Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Biologics Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Antisense, RNAi, And Molecular Therapy, Monoclonal Antibodies, Other Biologics, Recombinant Proteins, and Vaccines.
  • Based on Application, market is studied across Cardiovascular Diseases, Immunology, Infectious Diseases, Neurology, Oncology, and Other Applications. The Immunology is further studied across Allergic Disorders and Autoimmune Diseases. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Cancer Biomarker Studies and Personalized Cancer Treatments.
  • Based on Source, market is studied across Mammalian and Non-Mammalian. The Non-Mammalian is further studied across Bacteria, Insect Cells, Plant Cells, and Yeast.
  • Based on Service Type, market is studied across Analytical And Quality Control, Clinical Trials, Fill And Finish Operations, Process Development, and Regulatory Services.
  • Based on End User, market is studied across Biotechnology Companies, Contract Research Organizations (CROs), Pharmaceutical Companies, and Research Institutes.
  • Based on Therapeutic Area, market is studied across Cancer, Cardiovascular Diseases, Infectious Diseases, Inflammatory And Immune Disorders, Metabolic Disorders, and Neurological Conditions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Stringent regulatory requirements and the need for compliance expertise in biologics production
      • 5.1.1.2. Cost-efficiency and time reduction benefits driving outsourcing of biologics manufacturing
      • 5.1.1.3. Expansion of biologics pipelines by pharmaceutical companies necessitating external manufacturing support
      • 5.1.1.4. Adoption of single-use technologies and continuous bioprocessing by outsourcing firms
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of skilled workforce for specialized biologics manufacturing and process development
      • 5.1.2.2. Variability in biological product quality during outsourcing leading to potential risks and liabilities
    • 5.1.3. Opportunities
      • 5.1.3.1. Partnership opportunities with smaller biotechnology firms seeking affordable biologics manufacturing solutions
      • 5.1.3.2. Growing need for specialized biologics development services in niche therapeutic areas
      • 5.1.3.3. Rising collaboration between pharmaceutical companies and contract research organizations for biologics development
    • 5.1.4. Challenges
      • 5.1.4.1. Managing supply chain disruptions and logistics challenges in the biologics outsourcing market
      • 5.1.4.2. Ensuring cost efficiency while maintaining high quality standards in biologics outsourcing services
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Outsourcing Market, by Product Type

  • 6.1. Introduction
  • 6.2. Antisense, RNAi, And Molecular Therapy
  • 6.3. Monoclonal Antibodies
  • 6.4. Other Biologics
  • 6.5. Recombinant Proteins
  • 6.6. Vaccines

7. Biologics Outsourcing Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases
  • 7.3. Immunology
    • 7.3.1. Allergic Disorders
    • 7.3.2. Autoimmune Diseases
  • 7.4. Infectious Diseases
    • 7.4.1. Bacterial Infections
    • 7.4.2. Viral Infections
  • 7.5. Neurology
  • 7.6. Oncology
    • 7.6.1. Cancer Biomarker Studies
    • 7.6.2. Personalized Cancer Treatments
  • 7.7. Other Applications

8. Biologics Outsourcing Market, by Source

  • 8.1. Introduction
  • 8.2. Mammalian
  • 8.3. Non-Mammalian
    • 8.3.1. Bacteria
    • 8.3.2. Insect Cells
    • 8.3.3. Plant Cells
    • 8.3.4. Yeast

9. Biologics Outsourcing Market, by Service Type

  • 9.1. Introduction
  • 9.2. Analytical And Quality Control
  • 9.3. Clinical Trials
  • 9.4. Fill And Finish Operations
  • 9.5. Process Development
  • 9.6. Regulatory Services

10. Biologics Outsourcing Market, by End User

  • 10.1. Introduction
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations (CROs)
  • 10.4. Pharmaceutical Companies
  • 10.5. Research Institutes

11. Biologics Outsourcing Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cancer
  • 11.3. Cardiovascular Diseases
  • 11.4. Infectious Diseases
  • 11.5. Inflammatory And Immune Disorders
  • 11.6. Metabolic Disorders
  • 11.7. Neurological Conditions

12. Americas Biologics Outsourcing Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Biologics Outsourcing Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Biologics Outsourcing Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Biocon Limited
  • 4. Boehringer Ingelheim GmbH
  • 5. Catalent, Inc.
  • 6. Charles River Laboratories International, Inc.
  • 7. Covance Inc.
  • 8. Eli Lilly and Company
  • 9. Fujifilm Diosynth Biotechnologies
  • 10. Genentech, Inc.
  • 11. Icon plc
  • 12. Lonza Group AG
  • 13. Merck KGaA
  • 14. Novartis AG
  • 15. Parexel International Corporation
  • 16. Pfizer Inc.
  • 17. Samsung Biologics Co., Ltd.
  • 18. Sandoz International GmbH
  • 19. Thermo Fisher Scientific Inc.
  • 20. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS OUTSOURCING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. BIOLOGICS OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. BIOLOGICS OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS OUTSOURCING MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANTISENSE, RNAI, AND MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OTHER BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ALLERGIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CANCER BIOMARKER STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PERSONALIZED CANCER TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY OTHER APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BACTERIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PLANT CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY ANALYTICAL AND QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY FILL AND FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY REGULATORY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFLAMMATORY AND IMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS OUTSOURCING MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES BIOLOGICS OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. THAILAND BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. VIETNAM BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 266. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. DENMARK BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 276. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. EGYPT BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 286. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. FINLAND BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 296. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. FRANCE BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 305. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 306. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. GERMANY BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 315. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 316. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. ISRAEL BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 325. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 326. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. ITALY BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY NON-MAMMALIAN, 2018-2030 (USD MILLION)
  • TABLE 336. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 338. NETHERLANDS BIOLOGICS OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA BIOLOGICS